Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
Japan Cancels Purchase of 40 Million AstraZeneca Shots: Official
The Japanese government has canceled an order of 40 million COVID-19 vaccine doses from AstraZeneca, which constitute one-third of what it agreed to purchase in its supply pact inked in 2020, a health ministry official revealed on April 11. Yasuyuki…
To read the full story
Related Article
- Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
- Japan Can Get Refund on AstraZeneca Vaccine Cancellation: Minister
April 14, 2022
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines Up for Key Panel Review on May 20
May 17, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
- Health Minister Hails Domestic Production Plan for AstraZeneca Vaccine
February 8, 2021
- AstraZeneca Files COVID-19 Vaccine in Japan
February 5, 2021
- AstraZeneca, Japan Govt Ink Definitive Deal on COVID-19 Vaccine
December 11, 2020
- Japan to Earmark 671.4 Billion Yen to Secure Coronavirus Vaccines, Anticipating Final Agreements with 3 Companies
September 9, 2020
- AstraZeneca Launches Japan PI/II Study of COVID-19 Vaccine; Submission Could Be Possible Based on Results
September 7, 2020
- AstraZeneca to Supply 120 Million Doses of COVID-19 Vaccine to Japan
August 11, 2020
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- JCR in Talks with AstraZeneca on COVID-19 Vaccine Solution Manufacturing
August 3, 2020
- AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
- AstraZeneca in Talks with Daiichi Sankyo, Meiji Group on COVID-19 Vaccine Supplies in Japan
June 29, 2020
REGULATORY
- PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
- Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
- Aspirin, CAR-T and Other Products under PMDA Safety Review
December 8, 2025
- R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
- Another LDP Study Group Submits Emergency Proposal Urging Drug Pricing Overhaul
December 5, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…